gavi.org
VACCINE INVESTMENT
STRATEGY 2024 –
INVESTMENT CASES
BOARD MEETING
Marta Tufet
6 -7 June 2024, Geneva, Switzerland
PPC Recommendation: Support for learning agendas
and in-principle investments
2 Board Meeting, 6-7 June 2024
Vaccine PopulationIn
-principle
investment Learning
Agenda
Tuberculosis Adolescents/ Adults
 
Group B Streptococcus Pregnant women  
Dengue 2-16 years
Conditional
on burden data in Africa 
Hepatitis E
High-risk in outbreak
response  
from 5.1
Mpox 

from 5.1
Shigella Infants  
COVID-19 High-risk populations No continued investment post- 2025

gavi.org
GAVI 6.0 – THE ALLIANCE’S
STRATEGY 2026 -2030
BOARD MEETING
Johannes Ahrendts
6 -7 June 2024, Geneva, Switzerland
The design of Gavi 6.0 has followed three phases led
by the Board and informed by extensive country -
centric consultations
March
Board
Retreat
October
Board/PPC
mini -workshop
June
Board Meeting
December
Board Retreat
April
Board
Retreat
June
Board
Meeting
Feb -March
Board Task
Team
Define opportunities for impact
and indicative level of ambition
for Gavi 6.0
October – December 2023
Finalise strategic choices and
the new ‘one -pager’ framework
January – June 2024
Review of key contextual
trends
March – September 2023
1 2 3
Launch of the
Investment Opportunity
20 June 2024
2 Board Meeting, 6 -7 June 2024

gavi.org
GAVI 6.0 –ELIGIBILITY,
TRANSITION AND CO-
FINANCING MODEL, MIDDLE -
INCOME COUNTRIES
APPROACH AND
HEALTH SYSTEMS STRATEGY
BOARD MEETING
Benjamin Loevinsohn
Adriana Jimenez Cuen
Alex de Jonquières
6 -7 June 2024, Geneva, Switzerland
Based on feedback, we are suggesting a new variation to the options proposed last time
In 6.0 Gavi can build on the success of its ELTRACO
and MICs model and ensure it remains fit for purpose
The ELTRACO / MICs model has workedwellto date to drive
financial and programmatic sustainability But the model is facing challenges
The
MICs approach was added in 5.0 / 5.1
Co-financing and resources allocation for vaccines, US$ billion, 2011-2025
19 countries
transitioned out of Gavi support
Sustainability, health impact and
equity challenged by:
• Challenging macro-economic
outlook
• Rapidly increasing co -financing
levels
• Limited programmatic
readiness to transition
• Growing inequities in access to
immunisation including in a subset
of Former - and Never - Gavi -
eligible countries
1,124
Transitioned countries, including India
Co -financing obligations
Gavi 3.0 1,6
3,2
Gavi 4.0 Gavi 5.0 / 5.1
0,8
0,8 1,9
1,3
0,4
Note: Co -financing refers to the cost paid by Gavi -eligible countries for Gavi vaccine programmes including fully self -financed ones
Board Meeting, 6- 7 June 2024 2

gavi.org
FINANCIAL UPDATE, INCLUDING FORECAST
BOARD MEETING
Ian MacTavish
6-7 June 2024, Geneva, Switzerland
•2023 Statutory Financial Statements recommended to the
Board for approval by the AFC
• Majority of Gavi 5.1 Resources fully committed
• COVAX AMC Repurposing ongoing, outcome will be
significant
• It’s time for Organisational Effectiveness decisions!
2
Key Messages
Board Meeting, 6- 7 June 2024

gavi.org
CONSENT AGENDA
BOARD MEETING
6-7 June 2024, Geneva, Switzerland
Decision 1: Consent Agenda: Board Committee Chair
Appointment
2 Board Meeting, 6-7 June 2024
The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board that it :
a) Appoint
David Sidwell as an Unaffiliated Board Member in the seat currently held by
Naguib Kheraj, effective 1 August 2024 and until 31 July 2027; and
b) Appoint
the following as Chair of the Audit and Finance Committee effective 1 August 2024:
• David Sidwell (Board Member) until 31 December 2025

gavi.org
JOINT ALLIANCE UPDATE ON
IMPLEMENTATION OF GAVI 5.1
STRATEGY, PROGRAMMES
AND PARTNERSHIPS
BOARD MEETING
Aurélia Nguyen
Thabani Maphosa
Kate O’Brien
Ephrem Lemango
6 -7 June 2024, Geneva, Switzerland
Balanced Scorecard | Programmatic strategic goals
Strategic goal 2 Strengthen health systems
Baseline2023
Healthy market dynamics n/a 10
Incentivise innovations n/a 10
Scale -up innovations n/a 3
Strategic goal 4 Ensure healthy markets
Gavi 5.0
mission indicators
Baseline
2020
5.1
Cumulative
Unique children immunised 1 0 >133 million
Reduction in zero -dose children 9 million (2019) 10.2 million (2022)
Future deaths averted 0 >2.4 million
Future DALYs 2 averted 0 >121 million
Economic benefits unlocked 0>US$ 35.8 billion
SG2
SG4
** Updated bi-annually or more (else updated annually)
On track Delays/challenges Significant delays/challenges No target / TBD
Strategic goal 1 Introduce and scale up vaccines SG1
Baseline
2019 2022
Breadth of protection 48%56%
Timely outbreak detection 25% 3 18%
Measles campaign reach 37.3% (2021) 70.2%
Gavi 5.1
Cumulative, as of Dec
2023 2023
New vaccine introductions** 42 13
• HPV introductions** 14 6
• Malaria introductions** 00
Baseline
2021 2023
Co -financing fulfilment 100% (2020) 100% 4
Preventing backsliding in
Gavi -transitioned countries 8 countries 5 8 countries
(2022)
Vaccine intro in transitioned &
never -eligible countries n/a (2022) 5
Strategic goal 3 Improve sustainability SG3
Baseline
2019 2022
DTP3 coverage 83%81%
Geographic equity of DTP3 67%62%
DTP dropout 6%6%
MCV1 coverage 81%79%
GBS 1.0
1. Children immunised covers only routine immunisation, not campaigns 2. Disability Adjusted Life Years 3. Baseline for timely outbreak detection is average of 2018 –2020; 25 % out of 18 – for additional details refer to the Annual Progress Report from Gavi ; 18%
out of 40 – for additional details refer to the Annual Progress Report from Gavi 4 . % of countries who have fully met their co -financing obligation. Excluding countries whose co-financing obligation was exceptionally waived, all countries have fully met their 2023 co- financing obligation so far, with the exception of South Sudan, which has agreed to use its government contribution to a multi -donor trust fund to pay its remaining 2023 obligation .5. Baseline for preventing backsliding set for 2021 as of July 2022